Nervonik Inc., a neuromodulation company, has achieved significant milestones in preclinical testing of its innovative neural activity sensing technology during peripheral nerve stimulation (PNS) in large animal models. The company’s proprietary waveform and hardware enable the capture of neural signals in real-time during stimulation. This development is a critical step toward optimized electrode placement, precise programming, and future closed-loop therapy systems.
The technology captures Evoked Compound Action Potential (ECAP) and Compound Muscle Action Potential (CMAP), enhancing therapy precision, improving treatment outcomes, and reducing energy consumption. It lays the groundwork for personalized PNS therapies, particularly for chronic pain and neurological disorders. The findings are slated for presentation at conferences such as the North American Neuromodulation Society (NANS) early next year.
Nervonik’s PNS platform combines advanced hardware, wireless interfaces, and proprietary waveforms to push the boundaries of existing systems. The company is now working toward FDA clearance and early commercialization steps.
